Developer docs
API playgroundTry for free, no card

Search company profiles

BioStem Technologies

Full company profile

uuid0002xv3

Namestring
BioStem Technologies
Legal namestring
BioStem Technologies, Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

BioStem Technologies, Inc. (OTC: BSEM) is a publicly traded regenerative medicine company founded in 2014 and headquartered in Pompano Beach/Fort Lauderdale, Florida, that develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care. Its product portfolio includes the VENDAJE family (VENDAJE, VENDAJE AC, VENDAJE OPTIC), the American Amnion sub-brand, and — following the January 2026 acquisition of BioTissue Holdings' surgical and wound care business — the Neox and Clarix cryopreserved amniotic membrane allograft lines. Core technology is the proprietary BioREtain six-step processing method (disinfection, hematopoietic reduction, cold isotonic cleansing, gentle dehydration, precise cutting die placement, and low-dose e-beam terminal sterilization), protected by a portfolio of over 70 patents and manufactured in an AATB-accredited, FDA-registered, cGMP-compliant facility with ISO 5 and ISO 7 suites. BioStem sells direct to wound care physicians, podiatrists, and surgeons and distributes through partners including Venture Medical and the BioTissue-integrated hospital sales force, targeting diabetic foot ulcers, venous leg ulcers, chronic wounds, burns, ocular surface repair, and post-surgical applications under established Medicare HCPCS reimbursement.

The company generates revenue primarily through one-time product sales of allografts and transaction-fee distribution arrangements, with quote-based pricing tied to CMS reimbursement codes such as Q4252 for VENDAJE. Customer segments include wound care specialists, hospital systems, ambulatory surgery centers, and chronic wound patients including VA-adjacent populations. BioStem also operates a wholly owned CDMO subsidiary (BioStem Life Sciences) that offers formulation, regulatory, and supply chain services for biologics, HCT/Ps, and cell and gene therapies, providing optional third-party revenue. Recent strategic priorities include a planned Nasdaq uplisting (Form 10 filed; KPMG engaged as auditor), corporate governance upgrades (Jodi Ungrodt as Audit Committee Chair, Katherine Gorrell as Chief Legal & Compliance Officer), and geographic expansion via future headquarters at Florida Atlantic University's Research Park supporting up to 100 new jobs over five years.

Short descriptiontext

BioStem Technologies (OTC: BSEM) is a Florida-based regenerative medicine company that develops, manufactures, and commercializes perinatal tissue-derived allograft products (VENDAJE, Neox, Clarix lines) for advanced wound care, selling to physicians, hospitals, and ambulatory surgery centers via direct sales and distribution partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPompano Beach, United States
HQ citystring
Pompano Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
perinatal tissue allografts, advanced wound care, regenerative biologics, amniotic membrane products, skin substitute grafts
Industry3 codes
PRIMARYHLAKAAAF
Allergen Immunotherapy (SCIT/SLIT) Services
SECONDARYHLAAAKAJ
Packaging, Labeling & Serialization Services (biologics/cold chain)
SECONDARYHLAMAEAH
Dermatology & Allergy Drugs
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Regenerative Medicine / Wound Care Allografts
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales
TypeOne Time License
Description

BioStem generates revenue from the sale of perinatal tissue allograft products including VENDAJE, VENDAJE AC, VENDAJE OPTIC, American Amnion, Neox, and Clarix product lines. Products are sold to healthcare providers, hospitals, wound care centers, and through distribution partners.

biospace.com
2Distribution Fees
TypeTransaction Fee
Description

Revenue generated through distribution partnerships such as Venture Medical, where BioStem products are marketed and sold through the partner's network.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1VENDAJE
Description

Dehydrated human amniotic membrane (DHAM) allograft for protective covering of soft tissue wounds

biostemtechnologies.com
+6 more records
Core offering1 text field

BioStem Technologies develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care, surgical, and ocular surface applications. Its core offerings include dehydrated human amniotic membrane (VENDAJE) and dehydrated human amniotic/chorionic membrane (VENDAJE AC, American Amnion AC) allografts, an ultra-thin ocular allograft (VENDAJE OPTIC), and cryopreserved amniotic membrane allografts (Neox, Clarix), all produced using the proprietary BioREtain processing method at its cGMP, AATB-accredited, FDA-registered facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Nearly 2X probability of wound closure with BioRetain-processed allografts vs standard care in diabetic foot ulcers
+5 more records
Product overview1 text field

BioStem Technologies is a regenerative medicine company that develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care. The company's product portfolio includes the VENDAJE product line (VENDAJE, VENDAJE AC, VENDAJE OPTIC) and American Amnion sub-brand products, all processed using the proprietary BioREtain method that preserves endogenous biological properties of the tissue. Following the January 2026 acquisition of BioTissue Holdings' surgical and wound care business, the portfolio was expanded to include Neox and Clarix cryopreserved amniotic membrane allografts, extending commercial reach into hospital and surgical settings.

Product and service7 records
1VENDAJE
CategoryWound Care Allograft
Description

VENDAJE is a dehydrated human amniotic membrane (DHAM) allograft composed of the amnion layer of the placental membrane, intended as a protective covering for soft tissue wounds. It is sterilized via e-beam irradiation and stored at ambient temperature with a 4-year shelf life, designed for wound care specialists treating diabetic foot ulcers, venous leg ulcers, and other chronic or acute wounds.

2VENDAJE AC
CategoryWound Care Allograft
Description

VENDAJE AC is a dehydrated human amniotic/chorionic membrane (DHACM) allograft composed of both amnion and chorion layers of the placental membrane, intended as a protective covering for soft tissue wounds. The thicker multi-layer construction provides enhanced tissue protection for complex wounds and burns. HCPCS Q4252 code and Medicare reimbursement established across all MAC regions.

3VENDAJE OPTIC
CategoryOphthalmic Allograft
Description

VENDAJE OPTIC is an ultra-thin, dehydrated human amniotic membrane (DHAM) allograft intended for homologous use as a protective covering during the repair of ocular surfaces. It can be applied directly to the eye without additional hardware or sutures, targeting ophthalmic surgeons and ocular surface repair procedures.

4American Amnion
CategoryWound Care Allograft
Description

American Amnion is a dehydrated human amniotic membrane (DHAM) allograft manufactured using the proprietary BioRetain process, intended as a covering for homologous use in wound care applications. BioStem's sub-brand offering for wound care clinicians treating soft tissue wounds.

5American Amnion AC
CategoryWound Care Allograft
Description

American Amnion AC is a dehydrated human amniotic/chorionic membrane (DHACM) allograft manufactured using the proprietary BioRetain process, providing enhanced thickness and tensile strength for more robust wound covering applications. Sub-brand offering in the American Amnion line for advanced wound care.

6Neox
CategorySurgical Wound Care Allograft
Description

Neox is a cryopreserved amniotic membrane allograft product acquired from BioTissue Holdings and integrated into BioStem's wound care and surgical portfolio following the January 2026 acquisition. Designed for acute wound care and surgical applications in hospital inpatient, outpatient, and ambulatory surgery center settings.

7Clarix
CategorySurgical Wound Care Allograft
Description

Clarix is a cryopreserved amniotic membrane allograft product acquired from BioTissue Holdings and integrated into BioStem's wound care and surgical portfolio following the January 2026 acquisition. Used in surgical and acute wound care applications in hospital and ambulatory surgery center settings.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-23
Description

BioStem acquired BioTissue Holdings' non-ocular surgical and wound care business for up to $40 million, including $15 million upfront cash payment, $10 million potential FDA milestones, and $15 million commercial milestones. Acquisition includes Neox and Clarix cryopreserved amniotic membrane allograft product lines and BioTissue's surgical sales team. BioTissue continues manufacturing these products for BioStem.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-01-21
Description

Post-acquisition manufacturing agreement where BioTissue continues to manufacture Neox and Clarix products for BioStem, ensuring supply chain continuity while BioStem integrates the commercial organization.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership for nationwide launch of Vendaje AC following established reimbursement in all Medicare Administrative Contractor regions. Venture Medical provides sales and marketing support for physician office market.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration with clinical partners for randomized controlled trials on diabetic foot ulcers using Bayesian statistical methodologies, demonstrating superior outcomes with BioRetain-processed allografts.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MiMedx is the largest pure-play competitor in dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for wound care and surgical applications, directly competing with BioStem's VENDAJE and American Amnion lines on the same indications, reimbursement codes, and physician-office channel.

TypeBroad incumbent
Description

Coloplast operates a Wound & Skin Care business that markets skin-substitute and advanced wound care products to hospitals and home health providers, overlapping with BioStem's VENDAJE/Neox lines on the same DFU/VLU indications.

TypeEmerging player
Description

Sentry Biologics is an emerging regenerative medicine company marketing cryopreserved and dehydrated amniotic tissue allograft products for chronic and acute wound care, overlapping with BioStem's product portfolio on the same physician-office and hospital channels.

TypeBroad incumbent
Description

Smith+Nephew is a global medical device incumbent with a sizable Advanced Wound Management division (including skin substitute and biological dressing products) that competes with BioStem on hospital wound care contracts and DFU/VLU treatment pathways.

TypeEmerging player
Description

Vericel is a regenerative medicine company selling autologous and allogeneic cell-based therapies (MACI, Epicel) for cartilage repair and burns, with partial overlap to BioStem's wound-care tissue franchise in burn and complex-wound surgical applications.

TypeDirect peer
Description

Vivex Biomedical is a regenerative biologics company developing birth-tissue allograft products (including amniotic membrane grafts) for wound care and orthopedic applications, directly competing with BioStem's VENDAJE line; Dr. Wendy Weston, BioStem's VP of R&D, previously worked at Vivex.

TypeDirect peer
Description

Organogenesis is a regenerative medicine company selling Apligraf and Dermagraft living-cell skin substitutes and PuraPly amniotic products for chronic wound care, directly competing with BioStem's allograft portfolio in DFU/VLU and surgical wound applications.

TypeBroad incumbent
Description

ConvaTec's Advanced Wound Care division sells skin substitutes, antimicrobial dressings, and tissue-based products targeting the same DFU/VLU and chronic wound indications as BioStem's allograft portfolio across hospital and home-care channels.

TypeDirect peer
Description

Skye Biologics develops and commercializes human amniotic membrane and placental tissue allograft products (e.g., Affinity) for wound care and surgical applications, directly competing with BioStem on the same indications and reimbursement framework.

TypeBroad incumbent
Description

Integra LifeSciences is a diversified medical device incumbent with a regenerative tissue technologies and wound care portfolio (AmnioExcel, BioDFence) that overlaps with BioStem's allograft offerings as part of a broader neurosurgery, ENT, and reconstructive surgery franchise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioStem Technologies

Regenerative Medicine / Wound Care Allograftsbiostemtechnologies.com

BioStem Technologies (OTC: BSEM) is a Florida-based regenerative medicine company that develops, manufactures, and commercializes perinatal tissue-derived allograft products (VENDAJE, Neox, Clarix lines) for advanced wound care, selling to physicians, hospitals, and ambulatory surgery centers via direct sales and distribution partners.

What BioStem Technologies does

BioStem Technologies, Inc. (OTC: BSEM) is a publicly traded regenerative medicine company founded in 2014 and headquartered in Pompano Beach/Fort Lauderdale, Florida, that develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care. Its product portfolio includes the VENDAJE family (VENDAJE, VENDAJE AC, VENDAJE OPTIC), the American Amnion sub-brand, and — following the January 2026 acquisition of BioTissue Holdings' surgical and wound care business — the Neox and Clarix cryopreserved amniotic membrane allograft lines. Core technology is the proprietary BioREtain six-step processing method (disinfection, hematopoietic reduction, cold isotonic cleansing, gentle dehydration, precise cutting die placement, and low-dose e-beam terminal sterilization), protected by a portfolio of over 70 patents and manufactured in an AATB-accredited, FDA-registered, cGMP-compliant facility with ISO 5 and ISO 7 suites. BioStem sells direct to wound care physicians, podiatrists, and surgeons and distributes through partners including Venture Medical and the BioTissue-integrated hospital sales force, targeting diabetic foot ulcers, venous leg ulcers, chronic wounds, burns, ocular surface repair, and post-surgical applications under established Medicare HCPCS reimbursement.

The company generates revenue primarily through one-time product sales of allografts and transaction-fee distribution arrangements, with quote-based pricing tied to CMS reimbursement codes such as Q4252 for VENDAJE. Customer segments include wound care specialists, hospital systems, ambulatory surgery centers, and chronic wound patients including VA-adjacent populations. BioStem also operates a wholly owned CDMO subsidiary (BioStem Life Sciences) that offers formulation, regulatory, and supply chain services for biologics, HCT/Ps, and cell and gene therapies, providing optional third-party revenue. Recent strategic priorities include a planned Nasdaq uplisting (Form 10 filed; KPMG engaged as auditor), corporate governance upgrades (Jodi Ungrodt as Audit Committee Chair, Katherine Gorrell as Chief Legal & Compliance Officer), and geographic expansion via future headquarters at Florida Atlantic University's Research Park supporting up to 100 new jobs over five years.

BioStem Technologies firmographics

Firmographics
Name
BioStem Technologies
Legal name
BioStem Technologies, Inc.
Website
https://biostemtechnologies.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
BioStem Technologies (OTC: BSEM) is a Florida-based regenerative medicine company that develops, manufactures, and commercializes perinatal tissue-derived allograft products (VENDAJE, Neox, Clarix lines) for advanced wound care, selling to physicians, hospitals, and ambulatory surgery centers via direct sales and distribution partners.
Ownership category
akta.pro rank

BioStem Technologies industry classification

Industry
Product category
Regenerative Medicine / Wound Care Allografts
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAKAAAF
Allergen Immunotherapy (SCIT/SLIT) Services
SECONDARYHLAAAKAJ
Packaging, Labeling & Serialization Services (biologics/cold chain)
SECONDARYHLAMAEAH
Dermatology & Allergy Drugs
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

Keywords

  • Perinatal tissue allografts
  • Advanced wound care
  • Regenerative biologics
  • Amniotic membrane products
  • Skin substitute grafts

Where BioStem Technologies is headquartered

Location

Headquarters

HQ city
Pompano Beach
HQ country
United States
HQ region
North America

Offices3 records

Markets served

BioStem Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales: BioStem generates revenue from the sale of perinatal tissue allograft products including VENDAJE, VENDAJE AC, VENDAJE OPTIC, American Amnion, Neox, and Clarix product lines. Products are sold to healthcare providers, hospitals, wound care centers, and through distribution partners.
  2. Distribution Fees: Revenue generated through distribution partnerships such as Venture Medical, where BioStem products are marketed and sold through the partner's network.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

BioStem Technologies product offering

Product offering

Core offering

BioStem Technologies develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care, surgical, and ocular surface applications. Its core offerings include dehydrated human amniotic membrane (VENDAJE) and dehydrated human amniotic/chorionic membrane (VENDAJE AC, American Amnion AC) allografts, an ultra-thin ocular allograft (VENDAJE OPTIC), and cryopreserved amniotic membrane allografts (Neox, Clarix), all produced using the proprietary BioREtain processing method at its cGMP, AATB-accredited, FDA-registered facility.

Product overview

BioStem Technologies is a regenerative medicine company that develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care. The company's product portfolio includes the VENDAJE product line (VENDAJE, VENDAJE AC, VENDAJE OPTIC) and American Amnion sub-brand products, all processed using the proprietary BioREtain method that preserves endogenous biological properties of the tissue. Following the January 2026 acquisition of BioTissue Holdings' surgical and wound care business, the portfolio was expanded to include Neox and Clarix cryopreserved amniotic membrane allografts, extending commercial reach into hospital and surgical settings.

Differentiator

Problem solved

Functional benefit

Brands

  • VENDAJE: Dehydrated human amniotic membrane (DHAM) allograft for protective covering of soft tissue wounds
  • VENDAJE AC
  • VENDAJE OPTIC
  • American Amnion
  • Neox
  • Clarix
  • BioStem Life Sciences

Products and services

  • VENDAJE VENDAJE is a dehydrated human amniotic membrane (DHAM) allograft composed of the amnion layer of the placental membrane, intended as a protective covering for soft tissue wounds. It is sterilized via e-beam irradiation and stored at ambient temperature with a 4-year shelf life, designed for wound care specialists treating diabetic foot ulcers, venous leg ulcers, and other chronic or acute wounds.
  • VENDAJE AC VENDAJE AC is a dehydrated human amniotic/chorionic membrane (DHACM) allograft composed of both amnion and chorion layers of the placental membrane, intended as a protective covering for soft tissue wounds. The thicker multi-layer construction provides enhanced tissue protection for complex wounds and burns. HCPCS Q4252 code and Medicare reimbursement established across all MAC regions.
  • VENDAJE OPTIC VENDAJE OPTIC is an ultra-thin, dehydrated human amniotic membrane (DHAM) allograft intended for homologous use as a protective covering during the repair of ocular surfaces. It can be applied directly to the eye without additional hardware or sutures, targeting ophthalmic surgeons and ocular surface repair procedures.
  • American Amnion American Amnion is a dehydrated human amniotic membrane (DHAM) allograft manufactured using the proprietary BioRetain process, intended as a covering for homologous use in wound care applications. BioStem's sub-brand offering for wound care clinicians treating soft tissue wounds.
  • American Amnion AC American Amnion AC is a dehydrated human amniotic/chorionic membrane (DHACM) allograft manufactured using the proprietary BioRetain process, providing enhanced thickness and tensile strength for more robust wound covering applications. Sub-brand offering in the American Amnion line for advanced wound care.
  • Neox Neox is a cryopreserved amniotic membrane allograft product acquired from BioTissue Holdings and integrated into BioStem's wound care and surgical portfolio following the January 2026 acquisition. Designed for acute wound care and surgical applications in hospital inpatient, outpatient, and ambulatory surgery center settings.
  • Clarix Clarix is a cryopreserved amniotic membrane allograft product acquired from BioTissue Holdings and integrated into BioStem's wound care and surgical portfolio following the January 2026 acquisition. Used in surgical and acute wound care applications in hospital and ambulatory surgery center settings.

Quantifiable outcome

  • Nearly 2X probability of wound closure with BioRetain-processed allografts vs standard care in diabetic foot ulcers
  • +5 more outcomes

Companies that use BioStem Technologies

Customer profile

Segments3 records

Ideal customer profiles2 records

BioStem Technologies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

BioStem Technologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • BioTissue Holdings, Inc.coreStrategic or Co-development Partner · 23 January 2026BioStem acquired BioTissue Holdings' non-ocular surgical and wound care business for up to $40 million, including $15 million upfront cash payment, $10 million potential FDA milestones, and $15 million commercial milestones. Acquisition includes Neox and Clarix cryopreserved amniotic membrane allograft product lines and BioTissue's surgical sales team. BioTissue continues manufacturing these products for BioStem.
  • BioTissue Holdings, Inc.coreImplementation/ SI/ Consulting Partner · 21 January 2026Post-acquisition manufacturing agreement where BioTissue continues to manufacture Neox and Clarix products for BioStem, ensuring supply chain continuity while BioStem integrates the commercial organization.
  • Venture MedicalcoreChannel Partner/ Reseller/ DistributorDistribution partnership for nationwide launch of Vendaje AC following established reimbursement in all Medicare Administrative Contractor regions. Venture Medical provides sales and marketing support for physician office market.
  • Research institutions for clinical trialssupportingStrategic or Co-development PartnerCollaboration with clinical partners for randomized controlled trials on diabetic foot ulcers using Bayesian statistical methodologies, demonstrating superior outcomes with BioRetain-processed allografts.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

BioStem Technologies competitors and assessment

Company assessment

Direct peers

  • MiMedx Group: MiMedx is the largest pure-play competitor in dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for wound care and surgical applications, directly competing with BioStem's VENDAJE and American Amnion lines on the same indications, reimbursement codes, and physician-office channel.
  • Vivex Biomedical: Vivex Biomedical is a regenerative biologics company developing birth-tissue allograft products (including amniotic membrane grafts) for wound care and orthopedic applications, directly competing with BioStem's VENDAJE line; Dr. Wendy Weston, BioStem's VP of R&D, previously worked at Vivex.
  • Organogenesis Holdings: Organogenesis is a regenerative medicine company selling Apligraf and Dermagraft living-cell skin substitutes and PuraPly amniotic products for chronic wound care, directly competing with BioStem's allograft portfolio in DFU/VLU and surgical wound applications.
  • Skye Biologics: Skye Biologics develops and commercializes human amniotic membrane and placental tissue allograft products (e.g., Affinity) for wound care and surgical applications, directly competing with BioStem on the same indications and reimbursement framework.

Broad incumbents

  • Coloplast: Coloplast operates a Wound & Skin Care business that markets skin-substitute and advanced wound care products to hospitals and home health providers, overlapping with BioStem's VENDAJE/Neox lines on the same DFU/VLU indications.
  • Smith+Nephew: Smith+Nephew is a global medical device incumbent with a sizable Advanced Wound Management division (including skin substitute and biological dressing products) that competes with BioStem on hospital wound care contracts and DFU/VLU treatment pathways.
  • ConvaTec: ConvaTec's Advanced Wound Care division sells skin substitutes, antimicrobial dressings, and tissue-based products targeting the same DFU/VLU and chronic wound indications as BioStem's allograft portfolio across hospital and home-care channels.
  • Integra LifeSciences: Integra LifeSciences is a diversified medical device incumbent with a regenerative tissue technologies and wound care portfolio (AmnioExcel, BioDFence) that overlaps with BioStem's allograft offerings as part of a broader neurosurgery, ENT, and reconstructive surgery franchise.

Emerging players

  • Sentry Biologics: Sentry Biologics is an emerging regenerative medicine company marketing cryopreserved and dehydrated amniotic tissue allograft products for chronic and acute wound care, overlapping with BioStem's product portfolio on the same physician-office and hospital channels.
  • Vericel Corporation: Vericel is a regenerative medicine company selling autologous and allogeneic cell-based therapies (MACI, Epicel) for cartilage repair and burns, with partial overlap to BioStem's wound-care tissue franchise in burn and complex-wound surgical applications.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BioStem Technologies social profiles

Digital presence

BioStem Technologies compliance and trust

Trust signal

Compliance4 records

BioStem Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioStem Technologies leadership team

Management profile

Number of profiles

Profiles14 records

BioStem Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

BioStem Technologies funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioStem Technologies M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioStem Technologies

What does BioStem Technologies do?

BioStem Technologies develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care, surgical, and ocular surface applications. Its core offerings include dehydrated human amniotic membrane (VENDAJE) and dehydrated human amniotic/chorionic membrane (VENDAJE AC, American Amnion AC) allografts, an ultra-thin ocular allograft (VENDAJE OPTIC), and cryopreserved amniotic membrane allografts (Neox, Clarix), all produced using the proprietary BioREtain processing method at its cGMP, AATB-accredited, FDA-registered facility.

Is BioStem Technologies a public or private company?

BioStem Technologies is a public company. It is classified as public and is currently operating.

When was BioStem Technologies founded?

BioStem Technologies was founded in 2014. It employs 51 to 100 people.

Where is BioStem Technologies based?

BioStem Technologies is headquartered in Pompano Beach, United States, in the North America region.

How does BioStem Technologies make money?

Two revenue lines are on record. Product Sales are the primary driver. The others are distribution Fees.

Who are BioStem Technologies's main competitors?

Direct peers on record are MiMedx Group, Vivex Biomedical, Organogenesis Holdings and Skye Biologics. Broad incumbents are Coloplast, Smith+Nephew, ConvaTec and Integra LifeSciences. Emerging players are Sentry Biologics and Vericel Corporation.

Does BioStem Technologies have an API?

No public API is recorded for BioStem Technologies.

What industry is BioStem Technologies in?

BioStem Technologies's product category is Regenerative Medicine / Wound Care Allografts. Its primary akta.pro industry code is HLAKAAAF, Allergen Immunotherapy (SCIT/SLIT) Services, with a secondary code of HLAAAKAJ, Packaging, Labeling & Serialization Services (biologics/cold chain). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaBiostem outlines $10M-$12M annual cash opex cuts as it targets in-house manufacturing in H1 2027BioStem Technologies outlined $10M-$12M annual cash operating expense cuts in its Q3 2026 earnings call, targeting in-house manufacturing by the first half of 2027. The company's CEO said the third quarter marked its second full quarter operating as a predominantly hospital-focused business, with the focus now on executing a plan to accelerate its path to breakeven.American Banking and Market NewsContrasting BioStem Technologies (OTCMKTS:BSEM) and HCW Biologics (NASDAQ:HCWB)HCW Biologics and BioStem Technologies are compared on ratings, valuation, and profitability. HCW Biologics beats BioStem on 8 of 15 factors, with a consensus price target of $30 versus $9 and a higher potential upside. HCW's beta is 2.41, while BioStem's is 0.17.American Banking and Market NewsBioStem Technologies (OTCMKTS:BSEM) vs. Century Therapeutics (NASDAQ:IPSC) Critical ComparisonCentury Therapeutics and BioStem Technologies are compared on financials, ownership, and analyst ratings. BioStem has higher revenue ($292.21M vs $109.16M) and a lower P/E ratio, while Century has higher earnings. Analysts favor BioStem with a stronger consensus rating and higher upside.Medical BuyerBioStem Technologies announces private placementBioStem Technologies entered definitive agreements for a private placement of 735,296 shares and associated warrants at $4.08 per share. The offering is expected to close on September 30, 2026, with gross proceeds of approximately $3 million before expenses. Proceeds will be used for working capital and general corporate purposes.Investing.comBioStem Technologies raises $3M in private placementBioStem Technologies agreed to sell 735,296 shares and warrants in a private placement at $4.08 per share, expecting about $3 million in gross proceeds. The offering includes Series A and B warrants with exercise prices of $3.83, and the company plans to use net proceeds for working capital and general corporate purposes.TradingViewBioStem Technologies Secures $3 Million Private Placement; Issues Stock at $4.08 and WarrantsBioStem Technologies raised approximately $3 million through a private placement with institutional investors, issuing 735,296 common shares at $4.08 per share and warrants exercisable for up to 1,470,592 additional shares at $3.83. The placement closed on September 30, 2026, with proceeds for working capital and general corporate purposes. The company also executed a registration rights agreement to file a resale registration within 30 days.Markets DailyHead-To-Head Comparison: Caribou Biosciences (NASDAQ:CRBU) and BioStem Technologies (OTCMKTS:BSEM)Caribou Biosciences and BioStem Technologies are compared on valuation, profitability, and analyst ratings. Caribou has a higher consensus price target upside (525% vs 117%) and beats BioStem on 8 of 14 factors, though BioStem has higher revenue and lower volatility.Financial PostTerminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platformTerminal1 announced that BioStem Technologies has joined its platform, which integrates shareholder intelligence, investor communications, and digital investor relations tools. The move reflects public companies consolidating fragmented investor relations functions into a single system. Terminal1 continues expanding its customer base and capabilities.Pulse 2.0BioStem Technologies Secures Up To $40 Million Equity Facility From Roth Principal InvestmentsBioStem Technologies secured up to $40 million in equity from Roth Principal Investments, an affiliate of CR Financial Holdings. The company can issue and sell common stock to Roth over time, with proceeds for working capital and general corporate purposes. The facility supports BioStem's regenerative medicine expansion.AInvestBioStem Technologies (BSEM) Ignites 15.6% Surge on $40 Million Capital LifelineBioStem Technologies stock surged 15.6% to $5.04 after securing a $40 million committed equity facility with Roth Principal Investments. The deal caps dilution at 19.99% and provides working capital for commercializing allograft products. Technical indicators show bullish momentum with RSI near overbought.